Alex Marson is an Associate Professor at UCSF and scientific director of biomedicine at the Innovative Genomics Institute (IGI). His research goal is to understand the genetic circuits that control human immune cell function. His lab has developed new tools to accomplish efficient genome engineering in primary human immune cells with CRISPR. With this technology scientists can now readily re-write specific sequences in human cells and interrogate the biological effects. These advances in genome editing will accelerate fundamental insights into how immune cells are "wired" and have great potential to enhance the next generation of cell-based immunotherapies for cancer, infectious diseases, organ transplantation and autoimmune diseases.
Dr. Marson completed his MD/PhD training at Harvard/MIT, Internal Medicine residency at Brigham and Women’s and Infectious Diseases fellowship at UCSF. Alex was a UCSF Sandler Faculty Fellow from 2013-2016. Since 2016 he has been a UCSF faculty member in the Department of Microbiology and Immunology, with joint appointments in the Department of Medicine and the UCSF Diabetes Center. He is also a member of the Innovative Genomics Institute and the Helen Diller Family Comprehensive Cancer Center.
Dr. Marson has been recognized with the American Society of Clinical Investigation (ASCI) Young Physician-Scientist Award, the Burroughs Wellcome Foundation Career Award for Medical Scientists, and the NIDA/NIH Avenir New Innovator Award. In 2017, he was named one of the inaugural Chan Zuckerberg Biohub Investigators.
Jacob Corn is the founding Scientific Director of the Innovative Genomics Institute and faculty at UC Berkeley. His research aims to bring about the end of genetic disease through the development and application of next-generation genome editing technologies. Jacob is committed to the improvement of human health through the fundamental understanding of disease mechanisms. Over the last fifteen years he has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. His graduate studies at the University of California, Berkeley redefined our understanding of DNA replication and his postdoctoral work at the University of Washington computationally designed protein inhibitors from scratch. Prior to joining the Innovative Genomics Institute, Jacob was a group leader at Genentech where he discovered biological mechanisms for challenging therapeutic targets. In his spare time, Jacob enjoys long backpacking trips and rock climbing
Patrick Hsu is a Principal Investigator at the Salk Institute for Biological Studies. His research program integrates diverse approaches in molecular & synthetic biology, genomics, and bioengineering with a focus on gene regulation and tool development for the next generation of gene and cell therapies. CRISPR tools that systematically reverse-engineer cellular processes through rapid and precise perturbations are now allowing us to establish causal links between genetic changes and fundamental disease mechanisms. Recently, the Hsu lab discovered and developed novel CRISPR systems that expand the gene editing toolbox beyond DNA to RNA, and continues to build new approaches for cell design and control.
Patrick received his B.A. from the University of California, Berkeley, as well as A.M. and Ph.D. degrees from Harvard University. Working with Feng Zhang at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT, he contributed to the early development of CRISPR-Cas9 technologies for efficient and precise genome engineering in human cells. This work has been cited over 18,000 times. As a group leader at Editas Medicine, Patrick also previously directed preclinical discovery projects to translate these tools for treating human genetic disorders. He has been recognized for these contributions by Forbes' 30 Under 30 and the NIH Director's Early Independence Award.
Patrick can be found on Twitter or Google Scholar.